Prescription ·Strong evidence ·Reviewed May 2026
Ziprasidone is an atypical antipsychotic used for schizophrenia and bipolar I manic or mixed episodes. It has a clinically important QT-prolongation profile and oral absorption is strongly food dependent. Like other antipsychotics, it carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
The bottom line
Evidence rating strong. Most-documented uses: treatment of schizophrenia in adults, acute treatment of manic or mixed episodes in bipolar i disorder, maintenance treatment of bipolar i disorder as adjunct to lithium or valproate. 3 sources indexed (2020–2025), with 4 interaction records on file.
Core mechanism
Ziprasidone antagonizes dopamine D2 and serotonin 5-HT2A receptors and also has activity at several other serotonin receptors, with modest serotonin and norepinephrine reuptake inhibition. Antipsychotic and antimanic effects are primarily attributed to dopamine and serotonin receptor modulation. Its QT-prolonging effect is related to cardiac repolarization effects, so electrolyte abnormalities and other QT-prolonging agents increase arrhythmia risk.2,3
Food increases oral ziprasidone absorption up to about two-fold. Taking doses without a meal can substantially reduce exposure.2
Low magnesium can increase torsades de pointes risk in patients taking QT-prolonging drugs such as ziprasidone.
Recommendation: Correct magnesium deficiency under clinician guidance; do not use magnesium as a substitute for ECG or electrolyte monitoring in high-risk patients.
Hypokalemia increases QT-related arrhythmia risk during ziprasidone therapy.
Recommendation: Correct low potassium medically; avoid unsupervised potassium supplementation in kidney disease or with potassium-retaining drugs.
Melatonin can add to ziprasidone-related somnolence, dizziness, and impaired coordination.
Recommendation: Use cautiously and avoid driving or hazardous tasks until individual effects are known.
Ginkgo has seizure case reports, and antipsychotics including ziprasidone can lower seizure threshold in susceptible patients.
Recommendation: Avoid or use cautiously in patients with seizure history, brain injury, eating disorders, or other seizure-threshold-lowering drugs.
Numbered references. Citations throughout the page link here.
Guideline supports antipsychotic monitoring for movement disorders, metabolic effects, and cardiovascular risk.
Generic labeling emphasizes dose-related QT prolongation and contraindication with specified QT-prolonging drugs.
Labeling documents food-dependent absorption, QT contraindications, dosing, and the dementia-related psychosis boxed warning.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
